BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35898164)

  • 1. Optimizing CT and MRI criteria for differentiating intrahepatic mass-forming cholangiocarcinoma and hepatocellular carcinoma.
    Wu H; Liang Y; Wang Z; Tan C; Yang R; Wei X; Jiang X
    Acta Radiol; 2023 Mar; 64(3):926-935. PubMed ID: 35898164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LI-RADS Version 2018 Targetoid Appearances on Gadoxetic Acid-Enhanced MRI: Interobserver Agreement and Diagnostic Performance for the Differentiation of HCC and Non-HCC Malignancy.
    Min JH; Lee MW; Park HS; Lee DH; Park HJ; Lee JE; Park SJ; Kim SS; Park SH; Ha SY; Hwang JA; Cha DI; Park B
    AJR Am J Roentgenol; 2022 Sep; 219(3):421-432. PubMed ID: 35319906
    [No Abstract]   [Full Text] [Related]  

  • 3. Can contrast enhanced ultrasound differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma?
    Huang JY; Li JW; Ling WW; Li T; Luo Y; Liu JB; Lu Q
    World J Gastroenterol; 2020 Jul; 26(27):3938-3951. PubMed ID: 32774068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using Gd-EOB-DTPA-enhanced magnetic resonance imaging combined with serum markers in at-risk patients with hepatitis B virus.
    Han D; Li Y; He X; Zhang J; Zhou Y; Zhang J; Zhang L
    Quant Imaging Med Surg; 2023 Oct; 13(10):7156-7169. PubMed ID: 37869332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Added-value of ancillary imaging features for differentiating hepatocellular carcinoma from intrahepatic mass-forming cholangiocarcinoma on Gd-BOPTA-enhanced MRI in LI-RADS M.
    Zheng W; Huang H; She D; Xiong M; Chen X; Lin X; Cao D
    Abdom Radiol (NY); 2022 Mar; 47(3):957-968. PubMed ID: 34964069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI?
    Lee HS; Kim MJ; An C
    Eur Radiol; 2019 May; 29(5):2408-2416. PubMed ID: 30552477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.
    Kim R; Lee JM; Shin CI; Lee ES; Yoon JH; Joo I; Kim SH; Hwang I; Han JK; Choi BI
    Eur Radiol; 2016 Jun; 26(6):1808-17. PubMed ID: 26373763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An improved diagnostic algorithm for subcentimeter hepatocellular carcinoma on gadoxetic acid-enhanced MRI.
    Huang P; Zhou C; Wu F; Xiao Y; Qian X; Wang Y; Yang C; Zeng M
    Eur Radiol; 2023 Apr; 33(4):2735-2745. PubMed ID: 36472696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multi-center diagnostic system for intrahepatic mass-forming cholangiocarcinoma based on preoperative MRI and clinical features.
    Sheng R; Zhang Y; Wang H; Zhang W; Jin K; Sun W; Dai Y; Zhou J; Zeng M
    Eur Radiol; 2024 Jan; 34(1):548-559. PubMed ID: 37552257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI.
    Hwang J; Kim YK; Park MJ; Lee MH; Kim SH; Lee WJ; Rhim HC
    J Magn Reson Imaging; 2012 Oct; 36(4):881-9. PubMed ID: 22730271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinguishing intrahepatic mass-forming biliary carcinomas from hepatocellular carcinoma by computed tomography and magnetic resonance imaging using the Bayesian method: a bi-center study.
    Ichikawa S; Isoda H; Shimizu T; Tamada D; Taura K; Togashi K; Onishi H; Motosugi U
    Eur Radiol; 2020 Nov; 30(11):5992-6002. PubMed ID: 32500195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DCE-MRI based radiomics nomogram for preoperatively differentiating combined hepatocellular-cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma.
    Zhou Y; Zhou G; Zhang J; Xu C; Zhu F; Xu P
    Eur Radiol; 2022 Jul; 32(7):5004-5015. PubMed ID: 35128572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis after Curative Resection of Single Hepatocellular Carcinoma with A Focus on LI-RADS Targetoid Appearance on Preoperative Gadoxetic Acid-Enhanced MRI.
    Moon JY; Min JH; Kim YK; Cha D; Hwang JA; Ko SE; Choi SY; Yun EJ; Kim SW; Won HJ
    Korean J Radiol; 2021 Nov; 22(11):1786-1796. PubMed ID: 34402243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Intravoxel Incoherent Motion in Discriminating Hepatitis B Virus-Related Intrahepatic Mass-Forming Cholangiocarcinoma from Hepatocellular Carcinoma Based on Liver Imaging Reporting and Data System v2018.
    Shao S; Shan Q; Zheng N; Wang B; Wang J
    Cancer Biother Radiopharm; 2019 Oct; 34(8):511-518. PubMed ID: 31314589
    [No Abstract]   [Full Text] [Related]  

  • 15. Identification of Imaging Predictors Discriminating Different Primary Liver Tumours in Patients with Chronic Liver Disease on Gadoxetic Acid-enhanced MRI: a Classification Tree Analysis.
    Park HJ; Jang KM; Kang TW; Song KD; Kim SH; Kim YK; Cha DI; Kim J; Goo J
    Eur Radiol; 2016 Sep; 26(9):3102-11. PubMed ID: 26634931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI.
    Joo I; Lee JM; Lee SM; Lee JS; Park JY; Han JK
    J Magn Reson Imaging; 2016 Nov; 44(5):1330-1338. PubMed ID: 27087012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multivariate model based on gadoxetic acid-enhanced MRI using Li-RADS v2018 and other imaging features for preoperative prediction of dual‑phenotype hepatocellular carcinoma.
    Liu MT; Zhang JY; Xu L; Qu Q; Lu MT; Jiang JF; Zhao XC; Zhang XQ; Zhang T
    Radiol Med; 2023 Nov; 128(11):1333-1346. PubMed ID: 37740839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Modified Targetoid Feature Emphasizing Thin-Rim APHE to Improve the Diagnostic Performance of LI-RADS for Malignant Hepatic Tumors.
    Huang R; Zheng C; Xu G; Chen X; Shen J; Mao S
    J Hepatocell Carcinoma; 2024; 11():775-786. PubMed ID: 38689802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features?
    Joo I; Lee JM; Lee DH; Jeon JH; Han JK
    Eur Radiol; 2019 Apr; 29(4):1724-1732. PubMed ID: 30255250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid.
    Semaan S; Vietti Violi N; Lewis S; Chatterji M; Song C; Besa C; Babb JS; Fiel MI; Schwartz M; Thung S; Sirlin CB; Taouli B
    Eur Radiol; 2020 Feb; 30(2):1020-1030. PubMed ID: 31673837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.